Future research on the mechanisms by which SHH activators like SAG are regulating neuron–glia cross talk in experimental models of the disease will shed light on the possibility to modulate this pathway to target and limit/arrest neurodegeneration not only in FRDA, but also in other neurodegenerative diseases. This evidence concerns the gene SAG and Friedreich ataxia.